Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $34.1667.

Several research analysts recently commented on DYN shares. TD Cowen initiated coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating on the stock. Sanford C. Bernstein boosted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 15th. Finally, Cantor Fitzgerald initiated coverage on shares of Dyne Therapeutics in a report on Thursday. They set an “overweight” rating on the stock.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $25.63 on Tuesday. Dyne Therapeutics has a one year low of $8.88 and a one year high of $26.12. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The company has a 50 day moving average price of $20.56 and a 200 day moving average price of $18.67. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of -7.96 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) EPS. Sell-side analysts anticipate that Dyne Therapeutics will post -3.01 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 297,211 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total value of $6,913,127.86. Following the transaction, the director directly owned 2,962 shares of the company’s stock, valued at $68,896.12. This trade represents a 99.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders purchased 9,000 shares of company stock worth $156,800 and sold 1,665,542 shares worth $36,321,576. 9.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently modified their holdings of the stock. Creative Planning boosted its holdings in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after acquiring an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares during the period. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $26,000. Caxton Associates LLP lifted its position in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.